CINECA IRIS Institutional Research Information System

PIPPIONE, Agnese Chiara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.258
EU - Europa 2.217
AS - Asia 748
AF - Africa 38
SA - Sud America 33
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.305
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.152
IT - Italia 774
IE - Irlanda 328
CN - Cina 315
SE - Svezia 243
DE - Germania 182
FR - Francia 141
GB - Regno Unito 122
AT - Austria 102
IN - India 97
CA - Canada 95
UA - Ucraina 82
VN - Vietnam 65
HK - Hong Kong 53
FI - Finlandia 49
JP - Giappone 36
BE - Belgio 35
KR - Corea 33
SG - Singapore 30
DK - Danimarca 28
IR - Iran 27
PL - Polonia 25
NL - Olanda 22
TW - Taiwan 21
BR - Brasile 16
NG - Nigeria 15
TR - Turchia 13
CH - Svizzera 12
CZ - Repubblica Ceca 12
SN - Senegal 12
ID - Indonesia 11
MY - Malesia 11
PK - Pakistan 11
PT - Portogallo 11
ES - Italia 10
AU - Australia 9
AR - Argentina 7
GR - Grecia 6
IQ - Iraq 6
BG - Bulgaria 5
BZ - Belize 5
CO - Colombia 5
MX - Messico 5
SK - Slovacchia (Repubblica Slovacca) 5
TH - Thailandia 5
CL - Cile 4
HR - Croazia 4
MA - Marocco 4
NO - Norvegia 4
RU - Federazione Russa 4
UZ - Uzbekistan 4
CI - Costa d'Avorio 3
PH - Filippine 3
RS - Serbia 3
EG - Egitto 2
EU - Europa 2
GE - Georgia 2
HU - Ungheria 2
MK - Macedonia 2
RO - Romania 2
SA - Arabia Saudita 2
ZA - Sudafrica 2
BD - Bangladesh 1
BO - Bolivia 1
CU - Cuba 1
EE - Estonia 1
IL - Israele 1
LV - Lettonia 1
SY - Repubblica araba siriana 1
Totale 6.305
Salva come PNG Salva come JPEG
Città #
Chandler 549
Dublin 321
Torino 184
Nyköping 148
Ann Arbor 146
Los Angeles 116
Beijing 114
Turin 108
Houston 106
Vienna 102
Ashburn 100
Fairfield 99
Woodbridge 95
Jacksonville 93
Medford 86
Redwood City 77
Princeton 71
Wilmington 65
Villeurbanne 64
Dearborn 62
Fremont 56
Seattle 55
Cambridge 42
Dong Ket 41
Ottawa 40
Milan 36
Pisa 34
Brussels 32
Guangzhou 26
Rome 23
Boston 21
New York 21
Shanghai 21
Copenhagen 20
Nanjing 20
Québec 19
Warsaw 17
Toronto 16
Hangzhou 15
Munich 15
Washington 15
San Diego 14
Boardman 13
Menlo Park 13
Abuja 12
Bradford 12
Piemonte 12
Central 11
Ypsilanti 11
Delhi 10
Hefei 10
Paris 10
Chengdu 9
Jakarta 9
Singapore 9
Bari 8
Gunzenhausen 8
Hebei 8
Jinan 8
Kuala Lumpur 8
Rivoli 8
Siena 8
Tai Wan 8
Taichung 8
Taipei 8
Tokyo 8
Viterbo 8
Alessandria 7
Birmingham 7
Leeds 7
Leinì 7
Lisbon 7
Norwalk 7
Novara 7
Riverside 7
Amsterdam 6
Cassano Magnago 6
Chennai 6
Cleveland 6
Duncan 6
Epsom 6
Hamburg 6
Helsinki 6
Luzhou 6
Mumbai 6
Naples 6
Philadelphia 6
Seongbuk-gu 6
Barcelona 5
Belize City 5
Bratislava 5
Manchester 5
Reston 5
San Jose 5
Toledo 5
Uppsala 5
Valdagno 5
Buffalo 4
Carpi 4
Central District 4
Totale 3.733
Salva come PNG Salva come JPEG
Nome #
Androgen-AR axis in primary and metastatic prostate cancer: chasing steroidogenic enzymes for therapeutic intervention 316
DHODH inhibitors and leukemia: an emergent interest for new myeloid differentiation agents 243
PROCEEDINGS OF THE MERCK & ELSEVIER YOUNG CHEMISTSSYMPOSIUM 239
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors able to restore in vitro and in vivo myeloid differentiation 223
Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: Application of a bioisosteric scaffold hopping approach to flufenamic acid 185
Substituted 4-hydroxy-1,2,3-triazoles: synthesis, characterization and first drug design applications through bioisosteric modulation and scaffold hopping approaches 165
Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach 161
Design, synthesis, biological evaluation and X-ray structural studies of potent human dihydroorotate dehydrogenase inhibitors based on hydroxylated azole scaffolds 153
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action 151
Development of Potent Human Dihydroorotate Dehydrogenase Inhibitors Able to Induces Myeloid Differentiation 149
Design, synthesis, and biological evaluation of flufenamic acid derived bioisosteres as inhibitors of aldo-keto reductase 1C3 (AKR1C3) expressed in prostate cancer 144
NEW HYDROXYAZOLES INHIBITORS OF ALDO-KETO REDUCTASE 1C3 (AKR1C3) OBTAINED BY SCAFFOLD HOPPING FROM FLUFENAMIC ACID AND INDOMETHACIN FOR CASTRATE RESISTANT PROSTATE CANCER 138
N-Acetyl-3-aminopyrazoles block the non canonical NF-kB cascade by selectively inhibiting NIK 117
New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold 111
4-Hydroxy-N-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide: a novel inhibitor of the canonical NF-κB cascade 109
Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3 106
New inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3) based on benzoisoxazole scaffold and their potential application in cancer 106
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors 105
TOWARD A BIOISOSTERIC ALKAEST – APPLICATION TO THE BIOISOSTERIC MODULATION OF IMD-0354 101
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 100
Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies 98
Targeting Castration Resistant Prostate Cancer (CRPC) by innovative AKR1C3 inhibitors based on the 3-hydroxybenzoisoxazole structure 96
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentatomic Heterocycles 95
A differentiating and apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 91
Towards a Bioisosteric Alkaest: application to the bioisosteric modulation of IMD-0354 87
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by combination of in-silico ligand/structural pharmacophore models and scaffold hopping bioisosteric approaches 86
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentaatomic Heterocycles 85
Discovery and optimization of new OvCHT1 inhibitors based on the 4-hydroxy-1H-1,2,3-triazole ring 82
Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease 81
1H-pyrazole-4-carboxylic acids active against Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH): discovery of a new scaffold for development of antimalarial agents 81
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold: SAR of the Biphenyl Moiety 81
Development of new hydroxypyrazole-based inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) 80
NEW HYDROXYAZOLES INHIBITORS OF AKR1C3 OBTAINED FROM NSAIDS BY SCAFFOLD HOPPING APPROACH AGAINST CASTRATE RESISTANT PROSTATE CANCER 78
New Hydroxybenzoazole Inhibitors of Aldo-Keto Reductase 1C3 (AKR1C3): Disclosure of SAR Investigation to Target Prostate Cancer 77
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase inhibitors 76
Targeting myeloid differentiation using potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 71
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors 70
Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication 70
A differentiating and apoptotic therapy for acute myeloid leukaemia using potent human dihydroorotate dehydrogenase inhibitors. 69
Design, synthesis and co-crystallization of new Plasmodium falciparum dihydroorotate dehydrogenase inhibitors based on hydroxypyrazole scaffold 66
Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy 65
SUBSTITUTED 4-HYDROXY-1H-1,2,3-TRIAZOLES: SYNTHESIS AND BIOISOSTERIC APPLICATIONS 64
Heterocyclic ring cleavage upon collision-induced dissociation of deprotonated 3-hydroxy-1,2,5-oxadiazoles (3-hydroxyfurazans) 63
AKR1C3 is a biomarker and druggable target for oropharyngeal tumors 63
Improvement of in vivo pharmacokinetic profile of M433, a potent and innovative hDHODH inhibitor. 59
A new pro-apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 58
The synergism between DHODH inhibitors and dipyridamole leads to metabolic lethality in acute myeloid leukemia 57
Synthesis of new Plasmodium Falciparum dihydroorotate dehydrogenase inhibitors through the application of an isosteric portfolio 49
Regioselective N‐Alkylation of Ethyl 4‐Benzyloxy‐1,2,3‐triazolecarboxylate: A Useful Tool for the Synthesis of Carboxylic Acid Bioisosteres 48
Preliminary ADME/PK studies of new hDHODH inhibitors effective for treatment of acute myeloid leukaemia (AML) 46
Dihydroorotate dehydrogenase inhibitors in anti-infective drug research 46
Multiple-targeting ligands for AKR1C3 enzyme and androgen receptor to target prostate cancer 46
Apoptotic and differentiating therapy for AML using potent human dihydroorotate dehydrogenase inhibitor 45
Hydroxyazoles as acid isosteres and their drug design applications—Part 2: Bicyclic systems 44
Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with hydroxypyrazole core: new scaffolds against malaria disease 43
Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia 43
Synthesis of [18F]Brequinar as PET Imaging probes for human dihydroorotate dehydrogenase 43
The inhibition of human DHODH by M433 leads to differentiation and apoptosis in acute myeloid leukemia 42
Design, synthesis and co-crystallization of new Plasmodium falciparum dihydroorotate dehydrogenase inhibitors based on hydroxypyrazole scaffold 41
Hydroxylated heterocycles as a bioisosteric tool to Modulate the carboxylic function into design potent human Dihydroorotate Dehydrogenase inhibitors 41
Synthesis, physiochemical proprieties and application of hydroxyazole systems as carboxylic acid isoster 40
Improvement of metabolic weakness of new human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold 40
Preliminary ADME/PK studies of new hDHODH inhibitors effective for treatment of acute myeloid leukaemia (AML) 39
Targeting myeloid leukemias using human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold: overcoming of metabolic issues 38
Antileishmanial activity of some 4-phenyl-3-amino-1H-pyrazols designed as CRK3 kinase inhibitors 37
Develop of new fluorescent probe to target hDHODH enzyme 35
Hydroxyazoles as acid isosteres and their drug design applications—Part 1: Monocyclic systems 35
A New NF-κB Inhibitor, MEDS-23, Reduces the Severity of Adverse Post-Ischemic Stroke Outcomes in Rats 35
Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentatomic Heterocycles 35
Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3) 32
New human dihydroorotate dehydrogenase inhibitors able to restore myeloid differentiation in AML 32
Dopaminergic therapies modulate the T-CELL proteome of patients with Parkinson's disease 31
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Aryloxyaryl Moiety 29
Toward a Bioisosteric Alkahest: Targeting the human Dihydroorotate Dehydrogenase (hDHODH) by a Scaffold Hopping Bioisosteric approach using Hydroxylated Pentatomic Heterocycles 29
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic 28
Targeting Myeloid Leukemias Using human Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: Overcoming of Metabolic Issues 27
HYDROXYLATED HETEROCYCLES AS BIOISOSTERES OF THE CARBOXYLIC FUNCTION: DESIGN OF NEW AKR1C3 INHIBITORS ACTIVE IN PROSTATE CANCER 27
Synthesis of [18F] Brequinar as PET Imaging probes for human dihydroorotate dehydrogenase 26
Important steps into drug development of MEDS433, a potent human dihydroorotate dehydrogenase inhibitor based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold 25
Improving the fluorescent profile of pyrazolo [1,5-a]pyridine fluorophores for developing new fluorescent probes 24
Application of an in house bioisosteric approach to the design of innovative inhibitors of aldo-keto reductase 1C3 (AKR1C3) 22
Important Steps into Drug Development of MEDS433, a Potent Human Dihydroorotate Dehydrogenase Inhibitor based on the 2-hydroxypyrazolo[1,5-a] Pyridine Scaffold 16
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias 16
Effects of new hydroxyazoles inhibitors of AKR1C3 on vitality of prostate and colorectal cancer cell lines 15
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2- hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic 14
A new generation of AKR1C3 inhibitors on the horizon: the 3- hydroxybenzazole approach to target prostate cancer 12
Synthesis of [18F]Brequinar as PET Imaging probes for human dihydroorotate dehydrogenase 11
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias 10
NEW AKR1C3 INHIBITORS WITH BENZOISOXAZOLE CORE: DESIGN, SYNTHESIS AND BIOLOGICAL ACTIVITY TO TARGET PROSTATE CANCER 9
Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer 4
Exploring the Potential of Sulfur Moieties in Compounds Inhibiting Steroidogenesis 4
Totale 6.525
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.262
article - articoli 0
book - libri 0
conference - conferenze 12.534
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.796
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019136 0 0 0 0 0 0 0 0 0 0 78 58
2019/2020737 61 32 25 76 39 98 113 42 57 75 70 49
2020/2021733 83 70 48 46 54 39 47 36 96 58 60 96
2021/20221.032 49 24 59 91 38 48 43 37 26 133 303 181
2022/20231.902 189 229 68 180 145 432 145 115 162 57 100 80
2023/2024931 128 140 81 68 77 124 148 45 13 105 2 0
Totale 6.525